MK 0852

a cyclic heptapeptide antagonist of the platelet GP IIb/IIIa; structure given in first source

Also Known As:

L 367073; L-367,073; MK 852; MK-0852; MK-852; cyclo(Ac-Cys-Asn-Dmt-Amf-Gly-Asp-Cys); L-Cysteine, N-acetyl-L-cysteinyl-L-asparaginyl-5,5-dimethyl-L-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-, cyclic (1-7)-disulfide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bogaty, P: 1 article (12/2000)
2.	Kingma, J G: 1 article (12/2000)
3.	Plante, S: 1 article (12/2000)

Related Diseases

1.	Thrombosis (Thrombus) 09/01/1993 - "In a canine model of electrically induced LCX coronary artery thrombosis, i.v. MK-0852 (100 micrograms/kg + 3 micrograms/kg/min), initiated 15 min before the initiation of electrical injury, prevented occlusive thrombosis in 4 of 6 preparations despite the continued electrical stimulation of the vessel for 180 min. Thrombotic occlusion was delayed in the remaining two preparations (99 and 100 min), compared with occlusion in 4 of 4 saline-treated preparations (69.3 +/- 6.3 min). " 09/01/1993 - "Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis." 09/01/1993 - "MK-0852 was administered as an adjunctive therapy with tPA to evaluate its effects on thrombolysis after copper coil-induced femoral arterial thrombus formation. " 09/01/1993 - "In a canine model of copper coil-induced femoral arterial thrombosis, i.v. MK-0852 (100 micrograms/kg + 1 microgram/kg/min), initiated 15 min before coil placement, reduced the incidence of occlusive thrombosis during the 45-min post-coil time period of continued therapy (1/5 MK-0852 vs. 7/7 saline; P < .01). "
2.	Infarction (Infarctions) 12/01/2000 - "Diminished infarct size with MK-0852 treatment suggests an additional mechanism of benefit for GPIIb/IIIa blockers beyond stabilization of a "culprit" acute coronary lesion. " 12/01/2000 - "Infarct size in HEP-treated controls was 32.4+/-2.8%; in MK-0852 without or with HEP groups, infarct size was 17.4+/-1.9% (p = 0.001) and 23.4+/-3.0% (p = 0.04), respectively. "

Related Drugs and Biologics

1.	MK 0852
2.	Fibrinogen Receptors
3.	Copper

Related Therapies and Procedures

1.	Therapeutics